Cargando…

2238. Effect of Cefazolin Breakpoint Update in Susceptibility Reports on Antimicrobial Use

BACKGROUND: The Clinical Laboratory Standards Institute updated the breakpoints for cefazolin in the treatment of E. coli, Klebsiella, and Proteus (EKP) infections in 2011 to reflect doses used in clinical practice and achievable therapeutic concentrations in different body sites (urine vs. non-urin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buckley, Valerie, Scott Ferren, R, Zaidan, Noor, Britt, Rachel S, Reynoso, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677395/ http://dx.doi.org/10.1093/ofid/ofad500.1860

Ejemplares similares

87. Utilization of Methicillin-Sensitive/Resistant Staphylococcus aureus Nares Screen to Decrease Vancomycin and Linezolid Use in Hospitalized Patients with Respiratory Infections
por: Zaidan, Noor F, et al.
Publicado: (2020)

908. Impact of Antimicrobial Stewardship Protocol Mandating Infectious Diseases Consultation Post 72 Hours of Meropenem Usage
por: Nguyen, Nhi, et al.
Publicado: (2022)

167. Communication is Key: A Multifaceted Approach to Improving Essential ASP Metrics in Surgical Services
por: Britt, Rachel S, et al.
Publicado: (2020)

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
por: Cagnardi, Petra, et al.
Publicado: (2018)

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019)

274. Comparison of Cefazolin Susceptibilities of Enterobacterales with an Automated Susceptibility Testing Platform versus In Vitro Antimicrobial Testing
por: Noval, Mandee, et al.
Publicado: (2020)

1097. An Antimicrobial Stewardship Intervention to Optimize Cefazolin Dosing for Surgical Prophylaxis
por: Neuner, Elizabeth A, et al.
Publicado: (2019)

101. Serious Adverse Event Rates for Cefazolin and Ceftriaxone Outpatient Parenteral Antimicrobial Therapy
por: Sunagawa, Shawnalyn, et al.
Publicado: (2023)

Effect of the 2014 Clinical and Laboratory Standards Institute urine-specific breakpoints on cefazolin susceptibility rates at a community teaching hospital
por: Chastain, Daniel B., et al.
Publicado: (2017)

1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates
por: Pfaller, Michael A, et al.
Publicado: (2019)

1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
por: Pogue, Jason M, et al.
Publicado: (2019)

2238. Estimating the impact of antibiotic exposure on antibiotic resistance in uncomplicated UTI using machine learning causal inference
por: Kanjilal, Sanjat, et al.
Publicado: (2022)

1057. Treatment Efficacy of Ceftriaxone vs. Cefazolin for Methicillin-Susceptible Staphylococcus aureus Infections
por: Bhavan, Kavita, et al.
Publicado: (2018)

2238. Evaluation of Adjuvant Interferon-Gamma-Level Assessment to Improve the Performance of Procalcitonin Testing in Hospitalized Bacteremic Patients
por: Ololade, Shafiu O, et al.
Publicado: (2019)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

2262. Evaluation of Ceftriaxone Versus Cefazolin as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales Isolates
por: Lambert, Kaitlyn, et al.
Publicado: (2023)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus
por: Gern, Benjamin H., et al.
Publicado: (2018)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

217. Combination Salvage Therapy with Cefazolin Plus Ertapenem for Refractory Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Rose Ulloa, Erlinda, et al.
Publicado: (2019)

852. The Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children: Does It Matter?
por: McNeil, Jonathan C, et al.
Publicado: (2019)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

738. Outcomes of Ceftriaxone Versus Antistaphylococcal Penicillins or Cefazolin for Definitive Therapy of Methicillin-susceptible Staphylococcus aureus Bacteremia
por: Khodadadi, Ryan B, et al.
Publicado: (2022)

2238. Immunogenicity and safety of four- vs. three-standard doses HBV vaccination in HIV-infected adults with isolated anti-HBc antibody
por: Laksananun, Nattinee, et al.
Publicado: (2018)

301. Penicillin Versus Cefazolin or Anti-staphylococcal Penicillins for Penicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aldhaeefi, Mohammed, et al.
Publicado: (2020)

Antimicrobial Resistance: Beyond the Breakpoint
por: Pombo, David J.
Publicado: (2010)

Cefazolin and an aminoglycoside compared with cefazolin alone for the antimicrobial prophylaxis of type III open orthopedic fractures
por: Depcinski, Shawn C., et al.
Publicado: (2019)

2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
por: Kebriaei, Razieh, et al.
Publicado: (2018)

2533. Cerebrospinal Fluid Penetration of Cefazolin and Flucloxacillin in Children
por: Boast, Alison, et al.
Publicado: (2023)

2063. Extracellular Release of β-Lactamase Is Responsible for the Cefazolin Inoculum Effect (CzIE) in Methicillin-Susceptible Staphylococcus aureus
por: Carvajal, Lina P, et al.
Publicado: (2018)

2176. A New Rapid Test for Detection of The Cefazolin Inoculum Effect (CIE) in Methicillin-Susceptible Staphylococcus aureus (MSSA)
por: Carvajal, Lina P, et al.
Publicado: (2019)

346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
por: Poux, Nicolas, et al.
Publicado: (2023)

Should Cefazolin Be the First-line Antimicrobial Prophylaxis Choice in Patients Undergoing Hysterectomy? A Systematic Review and Meta-analysis
por: Pop-Vicas, Aurora, et al.
Publicado: (2017)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Cefazolin plus Clavulanic Acid Overcomes the Inoculum Effect in a Methicillin-Susceptible Staphylococcus aureus (MSSA) Rat Endocarditis Model
por: Miller, William, et al.
Publicado: (2017)

1453. Cephalexin and Cefadroxil Are Not Therapeutic Equivalents for Uncomplicated Cystitis (uUTI): Further Analysis of Cefazolin Surrogate Susceptibility Testing Criteria
por: Jones, Ronald N, et al.
Publicado: (2019)

850. Outcomes of Patients Discharged on Parenteral Ceftriaxone Compared with Oxacillin or Cefazolin in Methicillin-susceptible Staphylococcal aureus (MSSA) Bloodstream Infections
por: Erik Connor, Lee, et al.
Publicado: (2019)

1562. Safety and Efficacy of High-Dose Cefazolin Therapy in Obesity
por: Simpson, Timothy, et al.
Publicado: (2019)

1186. Cefazolin inoculum effect predicts reduced susceptibility to other antibiotics and patient outcomes in MSSA endovascular infections
por: Smelter, Dan, et al.
Publicado: (2020)

275. Comparison of Cefazolin versus Nafcillin for Methicillin-Susceptible Staphylococcus aureus Bacteremia with a Deep-Seated Source
por: Mersinger, Katherine E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ti0t2kc98jl2dijqfhr76vrhl8